As of April 12, 2021 – more than 6.8 million doses of the Johnson & Johnson (Janssen) vaccine have been administered in the U.S. The Centers for Disease Control (CDC) and the FDA are reviewing data involving six reported U.S. cases of a rare and severe type of blood clot in individuals after receiving the Johnson & Johnson vaccine. Right now, these adverse events appear to be extremely rare. The CDC will convene a meeting of the Advisory Committee on Immunization Practices (ACIP) on Wednesday, April 14th to further review these cases and assess their potential significance. The FDA will review that analysis as it also investigates these cases. Until that process is complete, we are recommending a pause in the use of this vaccine out of an abundance of caution.”
Read more about the Joint CDC and FDA statement on the Johnson & Johnson COVID-19 Vaccine.